Precision Medicine in Oncology®

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.

Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.

Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and potential future directions throughout the field.

The FDA has granted premarket approval to the Oncomine Dx Target Test for use as a companion diagnostic to identify patients with non–small cell lung cancer whose tumors harbor EGFR exon 20 insertion mutations who may be eligible to receive the newly approved small molecule TKI mobocertinib.

Mobocertinib plus ado-trastuzumab emtansine demonstrated inhibitory effects in HER2 exon 20 insertion–mutated lung cancer cell lines.

The European Association of Neuro-Oncology and ESMO have released clinical practice guidelines, which provide management recommendations for the diagnosis, treatment, and follow-up of patients with solid tumor brain metastases.

Genomic-adjusted radiation dose demonstrated a significant association with time to first recurrence and overall survival in patients with certain solid tumors who had been treated with radiation therapy, indicating that genomics should be used to guide radiation dosing decisions.

Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

The rapid development of novel agents directed at anaplastic lymphoma kinase gene fusions has emerged as one of the success stories of the targeted therapy era in non–small cell lung cancer

Jacob G. Scott, MD, DPhil, discusses the rationale to evaluate genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Overall survival was significantly improved at 18.6 months in patients with non–small cell lung cancer who received targeted therapy compared with those who did not receive targeted therapy at 11.4 months, according to a pooled analysis of patients who received National Comprehensive Cancer Network-guided therapies in accordance with their biomarkers.

The FDA has approved the VENTANA MMR RxDx panel as the first companion diagnostic test to assist in identifying patients with solid tumors that are DNA mismatch repair deficient who may be eligible to receive the anti–PD-1 therapy dostarlimab-gxly, which was recently granted an accelerated approval by the agency.

Circulating tumor DNA, tumor mutational burden, and homologous recombination deficiency are 3 emerging biomarkers for tailoring therapy need further clinical and technical clarity to support robust use in daily practice.

Drs. Brown and Kurzrock discuss the current and future applications of next-generation sequencing in breast cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.

Understanding the oncogenic drivers behind a cancer is taking on increasing importance as more effective agents targeting specific gene aberrations continue to emerge.

After nearly two decades of successfully developing therapies directed at molecular aberrations in non–small cell lung cancer, investigators are exploring a new generation of novel targets, including some not specifically associated with driver mutations.

Sonam Puri, MD, discusses the rationale to evaluate the real-world multiomic characterization of small cell lung cancer subtypes.

Hirva Mamdani, MD, discusses the rationale to evaluate the immunogenicity of STK11 and TP53 co-mutations in non–small cell lung cancer.

Abdul Rafeh Naqash, MD, discusses the results of a tumor profiling study in STK11 and TP53 co-mutated non–small cell lung cancer.

Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

Sukhmani K. Padda, MD, discusses strategies to overcome EGFR resistance in patients with non–small cell lung cancer.

Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

Dr. George and Dr. Hurley discuss the data generated from their study on the correlation between deleterious variants in genes and the development of hereditary breast and ovarian cancers in populations throughout the Caribbean.

Drs Brown and Husain discuss the current and future applications of next-generation sequencing in lung cancer, the role of tissue-based testing in light of the growing role for liquid-based testing, and some of the emerging technologies that could overcome current barriers to biomarker testing.